Despite surpassing earnings expectations for its fiscal fourth quarter, Arm Holdings faced a stock decline after issuing weaker-than-anticipated guidance. The chip designer’s outlook raised concerns among investors, overshadowing its recent performance.

After a strong rebound in early 2025, CVS Health’s stock offers an attractive 4% dividend yield. However, regulatory challenges and declining segments cast doubt on its future prospects. Should investors seize the opportunity or proceed with caution?